2.02
0.26 (14.77%)
| Penutupan Terdahulu | 1.76 |
| Buka | 1.89 |
| Jumlah Dagangan | 914,164 |
| Purata Dagangan (3B) | 1,004,611 |
| Modal Pasaran | 64,378,944 |
| Harga / Pendapatan (P/E Ke hadapan) | 1.48 |
| Harga / Jualan (P/S) | 129.89 |
| Harga / Buku (P/B) | 2.90 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 24 Mar 2026 |
| EPS Cair (TTM) | -1.96 |
| Nisbah Semasa (MRQ) | 0.220 |
| Aliran Tunai Operasi (OCF TTM) | -10.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 3.23 M |
| Pulangan Atas Aset (ROA TTM) | -191.74% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | NRX Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.25 |
|
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 15.88% |
| % Dimiliki oleh Institusi | 13.34% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Advisorshares Investments Llc | 31 Dec 2025 | 328,004 |
| Bleakley Financial Group, Llc | 31 Dec 2025 | 117,204 |
| One Wealth Management Investment & Advisory Services, Llc | 31 Dec 2025 | 37,873 |
| Chicago Partners Investment Group Llc | 31 Dec 2025 | 33,421 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 48.00 (Ascendiant Capital, 2,276.36%) | Beli |
| Median | 39.50 (1,855.54%) | |
| Rendah | 25.00 (BTIG, 1,137.69%) | Beli |
| Purata | 38.00 (1,781.28%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 1.98 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 09 Mar 2026 | 34.00 (1,583.25%) | Beli | 1.73 |
| 17 Feb 2026 | 34.00 (1,583.25%) | Beli | 1.80 | |
| HC Wainwright & Co. | 03 Mar 2026 | 45.00 (2,127.83%) | Beli | 1.80 |
| BTIG | 18 Feb 2026 | 25.00 (1,137.69%) | Beli | 1.78 |
| 15 Jan 2026 | 25.00 (1,137.69%) | Beli | 2.15 | |
| Ascendiant Capital | 02 Jan 2026 | 48.00 (2,276.36%) | Beli | 2.62 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |